earnings
confidence high
sentiment neutral
materiality 0.55
CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026
CalciMedica, Inc.
2025-Q2 EPS
reported -$0.76
vs consensus -$0.36
▼ miss
(-112.9%)
- Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.
- Cash and investments $18.0M; expected to fund operations into mid-2026.
- R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.
- Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.
- Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025.
item 2.02item 9.01